Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.54 |
| ▸ | PNLIP | P16233 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104417 | 1.00 | PTPN1 (0.54) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL4104413 | 0.82 | PTPN1 (0.54) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL26250198 | 0.79 | ALDH1A1 (0.46) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL25436073 | 0.78 | PTPN2 (0.64) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL25435120 | 0.78 | PTPN2 (0.64) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL25433754 | 0.78 | PTPN2 (0.64) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL25434992 | 0.78 | PTPN2 (0.64) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL25394431 | 0.77 | PTPN2 (0.67) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL25395835 | 0.77 | PNLIP (0.58) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 | |
| SCHEMBL25395895 | 0.77 | PTPN2 (0.67) | PTPN1PTPN2PNLIPCYP19A1RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240216456-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216457-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207344-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207342-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240108676-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-04-04 | — | — | US | disclosed |
| US-11883454-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230405067-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230346739-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230293480-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-20230293555-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-11684604-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220387537-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684604-B2 | Cannabis based therapeutic and method of use | CNR2, CNR1, OPRK1 | PTPN1 2536/4885PTPN2 2124/4885PNLIP 583/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | PTPN1 1893/4885PTPN2 2364/4885PNLIP 68/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | PTPN1 4282/4885PTPN2 4037/4885PNLIP 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.